These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9849417)

  • 1. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
    Stevenson JP; Scher RM; Kosierowski R; Fox SC; Simmonds M; Yao KS; Green F; Broom C; Fields SZ; Krebs JB; O'Dwyer PJ
    Eur J Cancer; 1998 Aug; 34(9):1358-62. PubMed ID: 9849417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
    Scher RM; Kosierowski R; Lusch C; Alexander R; Fox S; Redei I; Green F; Raskay B; Amfoh K; Engstrom PF; O'Dwyer PJ
    Invest New Drugs; 1996; 13(4):347-54. PubMed ID: 8824355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and clinical pharmacokinetic/pharmacodynamic basis for lack of efficacy of 21-day continuous topotecan in patients with untreated advanced adenocarcinoma of the pancreas.
    Mans DR; Di Leone L; Ferrary Caldas AP; Maino M; Almeida L; Cancela AI; Grivicich I; Brondani da Rocha A; Schwartsmann G
    Tumori; 2000; 86(6):458-64. PubMed ID: 11218186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma.
    Puls LE; Hunter JE; Crane MM
    Med Oncol; 2002; 19(1):25-33. PubMed ID: 12025888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
    Kindler HL; Kris MG; Smith IE; Miller VA; Grant SC; Krebs JB; Ross GA; Slevin ML
    Am J Clin Oncol; 1998 Oct; 21(5):438-41. PubMed ID: 9781595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
    Lorusso D; Mainenti S; Pietragalla A; Fusco E; Malaguti P; Masciullo V; Scambia G
    Oncology; 2011; 80(5-6):390-4. PubMed ID: 21829040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
    Gore M; Rustin G; Schüller J; Lane SR; Hearn S; Beckman RA; Ross G
    Br J Cancer; 2001 Apr; 84(8):1043-6. PubMed ID: 11308251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
    Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Levenback C; Chantarawiroj P; Gonzalez de Leon C; Kim EE; Madden T; Wallin B; Hord M; Verschraegen C; Raber M; Kavanagh JJ
    J Clin Oncol; 1996 May; 14(5):1552-7. PubMed ID: 8622071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
    Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
    J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
    Macdonald JS; Jacobson JL; Ketchel SJ; Weiss G; Taylor S; Mills G; Kuebler JP; Rivkin S; Conrad M
    Invest New Drugs; 2000 May; 18(2):199-202. PubMed ID: 10857998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
    O'Reilly S; Donehower RC; Rowinsky EK; Ord S; Grochow LB
    Anticancer Drugs; 1996 Jun; 7(4):410-4. PubMed ID: 8826609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
    Creemers GJ; Gerrits CJ; Schellens JH; Planting AS; van der Burg ME; van Beurden VM; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
    J Clin Oncol; 1996 Sep; 14(9):2540-5. PubMed ID: 8823333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
    Hütter G; Szélenyi H; Deckert PM; Keilholz U; Thiel E
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):178-84. PubMed ID: 15114411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.